GLP-1 medications such as Ozempic, Wegovy, and Mounjaro are rapidly reshaping conversations about weight, health, and treatment. But beyond the headlines, what do we really understand about these drugs — and where might this rapidly evolving field be heading?

 

As research expands and prescriptions increase worldwide, GLP-1 receptor agonists are generating both optimism and unease. Questions around long-term safety, effectiveness, access, equity, and the psychological implications of prescribing are becoming increasingly important for anyone navigating this emerging landscape — whether personally, professionally, or in supporting others.

 

This training moves beyond media narratives to explore what GLP-1 medications mean in real-world practice. You will gain balanced, up-to-date insights into the science behind these treatments, the potential benefits and limitations, and the broader context of how they are influencing approaches to weight and health.

 

Led by Bernie Wright, Lisa Smith, and Mel Ciavucco, this interactive session brings together expertise in counselling, nutrition, and health to unpack this complex and fast-moving topic with clarity, nuance, and thoughtful discussion.